Deutsche Bank’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Deutsche Bank’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,147	Closed	-$35K	–	4931
2021 Q1	$35K	Sell	10,147 -933	-8%	-$3.79K	﹤0.01%	4315
2020 Q4	$37K	Buy	11,080 +3,067	+38%	+$11K	﹤0.01%	4167
2020 Q3	$28K	Buy	8,013 +730	+10%	+$2.94K	﹤0.01%	4067
2020 Q2	$34K	Buy	7,283 +2,605	+56%	+$11.5K	﹤0.01%	3963
2020 Q1	$15K	Sell	4,678 -276	-6%	-$1.26K	﹤0.01%	3984
2019 Q4	$29K	Sell	4,954 -16,815	-77%	-$69.3K	﹤0.01%	4181
2019 Q3	$89K	Buy	21,769 +10,700	+97%	+$85.3K	﹤0.01%	3614
2019 Q2	$143K	Buy	+11,069	New	+$136K	﹤0.01%	4030
2019 Q1	–	Sell	-2,136	Closed	-$6K	–	5519
2018 Q4	$6K	Buy	+2,136	New	+$8.46K	﹤0.01%	4965

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Deutsche Bank's PHAS Position: Q2 2021 in Review

Deutsche Bank sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2021, closing a stake of 10,147 shares — an estimated $35K sold.

Deutsche Bank first reported a position in PHAS in Q4 2018 and held it in 9 quarters. The position peaked at $143K in Q2 2019. 55 funds tracked by Wall St. Rank hold PHAS as of Q2 2021.

Deutsche Bank reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Deutsche Bank sold 10,147 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $35K.
Deutsche Bank first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 9 quarters.
Deutsche Bank's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $143K in Q2 2019.
55 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Deutsche Bank's 13F filing for Q2 2021, filed 11 Aug 2021.